High Court Rebuffs Amgen, Lowering Bar For Investor Suits
Plaintiffs in securities fraud suits do not have to prove that allegedly misleading statements are material to a case for class certification, the U.S. Supreme Court ruled Wednesday in a landmark...To view the full article, register now.
Already a subscriber? Click here to view full article